Jazz Pharmaceuticals (FRA:J7Z) Cyclically Adjusted Revenue per Share: €46.12 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J7Z Jazz Pharmaceuticals PLC FRA:J7Z
73 GF Score
Price €218.00
GF Value €129.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Cyclically Adjusted Revenue per Share?

Jazz Pharmaceuticals FRA:J7Z -2.37% 73 Cyclically Adjusted Revenue per Share is €46.12 as of Mar. 2026. GuruFocus rates FRA:J7Z with a GF Score™ of 73/100 and a GF Value™ of €129.66 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Jazz Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was €13.988. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €46.12 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Jazz Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 13.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 12.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 17.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 20.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Jazz Pharmaceuticals was 24.10% per year. The lowest was 12.80% per year. And the median was 21.80% per year.

As of today (2026-08-01), Jazz Pharmaceuticals's current stock price is €218.00. Jazz Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €46.12. Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 4.73.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jazz Pharmaceuticals was 15.25. The lowest was 2.06. And the median was 5.31.


Jazz Pharmaceuticals  (FRA:J7Z) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=218.00/46.12
=4.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Jazz Pharmaceuticals was 15.25. The lowest was 2.06. And the median was 5.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Jazz Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Jazz Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.38 33.45 37.36 43.71 43.54

Jazz Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.80 41.49 42.60 43.54 46.12

FRA:J7Z vs BBIO, ASND, EXEL: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


FRA:J7Z
73GF Score
Jazz Pharmaceuticals PLC FRA:J7Z
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jazz Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=13.988/127.8300*127.8300
=13.988

Current CPI (Mar. 2026) = 127.8300.

Jazz Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 5.468 101.072 6.916
201609 5.395 100.274 6.878
201612 6.161 99.676 7.901
201703 5.747 100.374 7.319
201706 5.711 100.673 7.252
201709 5.624 100.474 7.155
201712 6.027 100.075 7.699
201803 5.894 100.573 7.491
201806 6.973 101.072 8.819
201809 6.503 101.371 8.200
201812 6.933 100.773 8.795
201903 7.743 101.670 9.735
201906 8.231 102.168 10.298
201909 8.500 102.268 10.625
201912 9.144 102.068 11.452
202003 8.648 102.367 10.799
202006 8.940 101.769 11.229
202009 9.072 101.072 11.474
202012 9.568 101.072 12.101
202103 8.740 102.367 10.914
202106 10.497 103.364 12.982
202109 11.625 104.859 14.172
202112 12.899 106.653 15.460
202203 11.745 109.245 13.743
202206 13.913 112.779 15.770
202209 15.132 113.504 17.042
202212 14.552 115.436 16.114
202303 11.304 117.609 12.286
202306 12.015 119.662 12.835
202309 12.777 120.749 13.526
202312 13.320 120.749 14.101
202403 13.269 120.990 14.019
202406 13.661 122.318 14.277
202409 15.046 121.594 15.818
202412 16.899 122.439 17.643
202503 13.614 123.405 14.102
202506 14.816 124.492 15.213
202509 15.574 124.810 15.951
202512 16.755 125.770 17.029
202603 13.988 127.830 13.988

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €46.12 mean?
Jazz Pharmaceuticals (FRA:J7Z) has a Cyclically Adjusted Revenue per Share of €46.12 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Jazz Pharmaceuticals' current Cyclically Adjusted Revenue per Share is €46.12. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to BBIO and ASND?
Jazz Pharmaceuticals' Cyclically Adjusted Revenue per Share of €46.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Cyclically Adjusted Revenue per Share is €46.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (FRA:J7Z) is currently considered Significantly Overvalued. The stock's GF Value™ is €129.66, compared to a current price of €218.00 — trading 68.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €46.12. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Jazz Pharmaceuticals (FRA:J7Z), the current Cyclically Adjusted Revenue per Share is €46.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (FRA:J7Z) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of €218.00 is trading 68.1% above its estimated GF Value™ of €129.66. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:J7Z:

  • Cyclically Adjusted Revenue per Share: €46.12
  • GF Value™: €129.66 vs. price of €218.00 (68.1% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the FRA:J7Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for FRA:J7Z

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€218.00
Price
€129.66
GF Value